Some researchers have also developed the tumor immune dysfunction and exclusion (TIDE) score [17,18], which is a method for predicting ICI treatment response by using a gene expression profile, which is superior to some biomarkers (such as TMB and PD-L1 level). This evidence concerns the gene CD274 and neoplasm.